An international consortium, including L’Oréal's BOLD, Evonik Venture Capital, and the DeepTech & Climate Fund, has invested €35 million in Abolis Biotechnologies to enhance its sustainable biotechnological innovations.

Target Company Overview

Abolis Biotechnologies, a French enterprise founded in 2014, specializes in the development of innovative biotechnological solutions utilizing microorganisms to aid industries in their transition towards more sustainable production methods. It recently completed a funding round of €35 million, aiming to enhance its research, development, and market expansion of biomanufacturing and microbiome solutions.

This capital injection reflects significant interest from industry leaders and impact-oriented investors alike, such as BOLD, the venture capital arm of L’Oréal, along with Evonik Venture Capital and the DeepTech & Climate Fund. By harnessing these resources, Abolis plans to strengthen its production processes and further develop its Biomanufacturing Studio, which focuses on decoding and advancing microbial ecosystems.

Industry Overview in France

France's biotechnology sector has been on a remarkable growth trajectory, benefiting from robust government support and increasing investments. As the demand for sustainable industrial solutions rises, biotechnology is positioned as a vital enabler of transformation across various in